(S)-1-BOC-3-异丁基哌嗪 | 928025-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (S)-1-BOC-3-异丁基哌嗪
• 中文别名: (3S)-3-(2-甲基丙基)-1-哌嗪甲酸叔丁酯
• 英文名称: tert-butyl (3S)-3-isobutylpiperazine-1-carboxylate
• 英文别名: (S)-1-Boc-3-isobutyl-piperazine；tert-butyl (3S)-3-(2-methylpropyl)piperazine-1-carboxylate
• CAS: 928025-62-1
• 化学式: C₁₃H₂₆N₂O₂
• mdl: MFCD07772108
• 分子量: 242.362
• InChiKey: LSZJZDBPJNYEIE-NSHDSACASA-N

物化性质

• 密度：
  0.962

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.923
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-1-BOC-3-异丁基哌嗪 在 碳酸氢钠 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 5.5h， 生成 benzyl (S)-4-(3-acetamido-5-fluorobenzoyl)-2-isobutylpiperazine-1-carboxylate
  参考文献：
  名称：

  [EN] ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS
  [FR] INHIBITEURS DU LYMPHOME 9 À ΒETA-CATÉNINE ET À LYMPHOCYTE B (BCL9)

  摘要：

  公开号：

  WO2020081918A3
• 作为产物：
  描述：

  tert-butyl (3S)-3-(2-methylpropyl)-4-(4-nitrophenyl)sulfonylpiperazine-1-carboxylate 在 1-辛硫醇 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 0.25h， 以329 mg的产率得到(S)-1-BOC-3-异丁基哌嗪
  参考文献：
  名称：

  Expedite Protocol for Construction of Chiral Regioselectively N-Protected Monosubstituted Piperazine, 1,4-Diazepane, and 1,4-Diazocane Building Blocks

  摘要：

  This paper describes the first study of solution-phase synthesis of chiral monosubstituted piperazine building blocks from nosylamide-activated aziridines. The protocol, involving aminolysis of the starting aziridines with omega-amino alcohols and subsequent Fukuyama-Mitsunobu cyclization, offers the advantage of mild conditions as well as short reaction times, and it leads to optically Pure N-Boc- or N-Ns-protected piperazines. This four-step sequence, requiring only a single final chromatographic purification, was extended to include novel diazepane and diazocane derivatives.

  DOI：

  10.1021/jo900441s

文献信息

• [EN] THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS THIAZOLO-PYRIMIDINE THÉRAPEUTIQUEMENT ACTIFS
  申请人：UCB PHARMA SA

  公开号：WO2013068458A1

  公开（公告）日：2013-05-16

  A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列噻唑并[5,4-d]嘧啶衍生物的化学式(I)或其N-氧化物，或其药用可接受的盐或溶剂：(I) Q代表化学式(Qa)、(Qb)、(Qc)、(Qd)或(Qe)的基团，在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥。
• Therapeutically Active Thiazolo-Pyrimidine Derivatives
  申请人：UCB Pharma S.A.

  公开号：US20140315885A1

  公开（公告）日：2014-10-23

  A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列噻唑并[5,4-d]嘧啶衍生物的化学式(I)或其N-氧化物，或其药用可接受的盐或溶剂：(I) Q代表化学式(Qa)、(Qb)、(Qc)、(Qd)或(Qe)的基团，在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥反应。
• [EN] THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLO-PYRIMIDINE THÉRAPEUTIQUEMENT ACTIFS
  申请人：UCB PHARMA SA

  公开号：WO2014096423A1

  公开（公告）日：2014-06-26

  A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4- position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseasesand malaria; and organ and cell transplant rejection.

  一系列在4-位被一种二氮杂单环、桥接的双环或螺环基团取代的吡唑并[3,4-d]嘧啶衍生物，在治疗和/或预防各种人类疾病方面具有益处，包括炎症、自身免疫和肿瘤性疾病；病毒性疾病和疟疾；以及器官和细胞移植排斥。
• Derivative having ppar agonistic activity
  申请人：Itai Akiko

  公开号：US20090286974A1

  公开（公告）日：2009-11-19

  A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl, Y 1 is a bond or —NR 6 — or the like, Ring A is optionally substituted nonaromatic heterocyclediyl, a group of the formula: -Y 2 Z 1 - is a group of the formula: R 7 are each independently hydrogen, optionally substituted lower alkyl or the like, R 8 and R 9 are each independently hydrogen or optionally substituted lower alkyl, n is an integer between 1 and 3, Z 1 is a bond, —O—, —S— or —NR 9 —, Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl, Y 3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, optionally substituted lower alkenylene or the like, and Z 2 is COOR 3 or the like.

  化合物的公式（I）：其药物可接受的盐或溶剂，其中环Q是可选择的取代的单环芳基，可选择的取代的单环杂芳基，可选择的融合芳基或可选择的融合杂芳基，Y1是键或-NR6-或类似物，环A是可选择的取代的非芳香杂环二基，公式组：-Y2Z1-是公式组：R7各自独立地是氢，可选择的取代的低烷基或类似物，R8和R9各自独立地是氢或可选择的取代的低烷基，n是1到3之间的整数，Z1是键，-O-，-S-或-NR9-，环B是可选择的取代的芳香碳杂环二基或可选择的取代的芳香杂环二基，Y3是键，可选择的取代的低烷基，可选择地介入-O-，可选择的取代的低烯基或类似物，并且Z2是COOR3或类似物。
• Therapeutically Active Pyrazolo-Pyrimidine Derivatives
  申请人：UCB PHARMA S.A.

  公开号：US20160194329A1

  公开（公告）日：2016-07-07

  A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

  一系列在4位点取代了含有一环氮杂原子的单环、桥环或螺环的嘧唑并[3,4-d]嘧啶衍生物，在治疗和/或预防各种人类疾病方面具有益处，包括炎症、自身免疫和肿瘤性疾病；病毒性疾病和疟疾；以及器官和细胞移植排斥反应。